SystImmune Inc Announces Appointment of Martín Sebastian Olivo, M.D. as Chief Medical Officer

/PRNewswire/ -- SystImmune, Inc. a clinical-stage company developing innovative cancer therapeutics, including novel bi-specific, multi-specific antibodies,...

Related Keywords

China ,Chengdu ,Sichuan ,Canada ,Buenos Aires ,Distrito Federal ,Argentina ,El Salvador ,Salvador ,Yi Zhu ,Martin Sebastian Olivo ,School Of Medicine ,While Systimmune Inc ,Austral University In Buenos Aires ,Eisai Inc ,University Of Buenos Aires ,Prnewswire Systimmune Inc ,Biokin Pharmaceutical Co Ltd ,Systimmune Inc ,Immunomedics Inc ,Securities Exchange ,Protara Therapeutics Inc ,Pharmacological Research ,Clinical Development At Gilead Sciences Inc ,University Of Salvador ,Chief Medical Officer ,Protara Therapeutics ,Chief Executive Officer ,Vice President ,Clinical Development ,Gilead Sciences ,Global Clinical ,Daiichi Sankyo Cancer Enterprise ,Austral University ,Clinical Oncologist ,Enrique Torn ,National Cancer Institute ,Canada Clinical Trials ,Redmond Washington ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,Investigational New Drug ,Systimmune ,Nc ,Pharmaceuticals ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Biotechnology ,Personnel Announcements ,